Related Experiment Video
Updated: Jun 24, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
[Paraneoplastic neurological syndromes]
Anette Storstein1, Christian A Vedeler
1astt@helse-bergen.no
Background:
Paraneoplastic neurological syndromes constitute a heterogenous group of diseases, which often cause severe neurological symptoms. Extensive research during the last 20 years has led to identification of new antigenic targets and inclusion of additional clinical conditions into this group of syndromes.
Material And Methods:
The article is based on a non-systematic search of PubMed and the author's own experience with antibody analysis, treatment of patients and research within the field.
Results And Interpretation:
Paraneoplastic neurological syndromes affect less than 1 % of all patients with cancer. The etiology is probably autoimmune, and involves immune responses (cellular and humoral) against antigens shared by tumor cells and normal neurons. Many, but not all patients harbour onconeural antibodies (in serum and spinal fluid), which are highly useful diagnostic markers for a paraneoplastic etiology. The cornerstone of therapy is treatment of the underlying tumor, but additional immunosuppressive therapy is often administered.
Insights
Paraneoplastic neurological syndromes (PNS) are autoimmune disorders affecting cancer patients. Early diagnosis and treatment of the primary tumor, alongside immunosuppression, are key for managing these rare but severe conditions.
Area of Science:
- Neurology
- Oncology
- Immunology
Context:
- Paraneoplastic neurological syndromes (PNS) are a diverse group of disorders characterized by severe neurological symptoms.
- Recent advancements have identified novel antigenic targets and expanded the clinical spectrum of PNS.
- PNS affect less than 1% of cancer patients, highlighting their rarity but significant impact.
Purpose:
- To review the current understanding of paraneoplastic neurological syndromes.
- To discuss the autoimmune etiology, diagnostic markers, and therapeutic strategies for PNS.
Summary:
- PNS result from immune responses targeting antigens shared by tumor cells and neural tissues.
- Onconeural antibodies in serum and cerebrospinal fluid are crucial diagnostic markers for PNS.
- Treatment involves addressing the underlying malignancy and employing immunosuppressive therapies.
Impact:
- Improved diagnostic capabilities through antibody detection.
- Enhanced therapeutic approaches combining tumor treatment and immunosuppression.
- Greater awareness and understanding of these complex neuro-oncological disorders.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Cushing Syndrome II: Pathophysiology
Alterations in Muscle Tone ll
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Multiple Sclerosis l: Introduction
